Similar articles

• PET studies of neuroreceptors in schizophrenia. Commentary on "The current status of PET scanning with respect to schizophrenia".

  Wong DF. Wong DF. Neuropsychopharmacology. 1992 Aug;7(1):69-72; discussion 73-5. Neuropsychopharmacology. 1992. PMID: 1388023 No abstract available.
• Elevated D2 in schizophrenia: role of endogenous dopamine and cerebellum. Commentary on "The current status of PET scanning with respect to schizophrenia".

  Seeman P. Seeman P. Neuropsychopharmacology. 1992 Aug;7(1):55-7; discussion 73-5. Neuropsychopharmacology. 1992. PMID: 1388022 No abstract available.
• PET scanning in schizophrenia, a critical evaluation. Commentary on "The current status of PET scanning with respect to schizophrenia".

  Murphy D, Rapoport SI. Murphy D, et al. Neuropsychopharmacology. 1992 Aug;7(1):59-61; discussion 73-5. Neuropsychopharmacology. 1992. PMID: 1524656 No abstract available.
• The current status of PET scanning with respect to schizophrenia.

  Sedvall G. Sedvall G. Neuropsychopharmacology. 1992 Aug;7(1):41-54. Neuropsychopharmacology. 1992. PMID: 1388021 Review.
• In vivo neuropharmacology of schizophrenia.

  Bigliani V, Pilowsky LS. Bigliani V, et al. Br J Psychiatry Suppl. 1999;(38):23-33. Br J Psychiatry Suppl. 1999. PMID: 10884897 Review. No abstract available.